Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline
Novartis AG (NYSE: NVS ) reported better-than-expected second-quarter earnings on Tuesday as strong demand for its priority medicines offset the impact of generic competition, while the Swiss drugmaker reaffirmed its full-year 2026 guidance. Adjusted earnings came in at $2.41 per share, topping the analyst consensus es